MARTINSRIED/MUNICH, Germany, Sept. 25 /PRNewswire-FirstCall/ -- Waltham, Mass. and Princeton, N.J. -- (Frankfurt Stock Exchange: GPC; TecDAX 30; Nasdaq: GPCB) today announced that it will hold a conference call today, Monday, September 25, 2006 to discuss positive results from the satraplatin pivotal phase 3 trial in second-line hormone refractory prostate cancer announced yesterday.

The call will be held today at 14:00 CEST/8:00 AM EDT. Participants may listen via live webcast, accessible through the GPC Biotech Web site at http://www.gpc-biotech.com or via telephone. A replay will be available via the Web site following the live event.

    The dial-in numbers for the call are as follows:

    European participants: 
    U.S. participants: 1- (toll-free)

is a biopharmaceutical company discovering and developing new anticancer drugs.

GPC Biotech's lead product candidate - satraplatin - has achieved target enrollment in a Phase 3 registrational trial as a second-line chemotherapy treatment in hormone-refractory prostate cancer. The U.S. FDA has granted fast track designation to satraplatin for this indication, and GPC Biotech has begun the rolling NDA submission process for this compound. GPC Biotech is also developing a monoclonal antibody with a novel mechanism-of-action against a variety of lymphoid tumors, currently in Phase 1 clinical development, and has ongoing drug development and discovery programs that leverage its expertise in kinase inhibitors. is headquartered in Martinsried/Munich (Germany), and its wholly owned U.S. subsidiary has sites in Waltham, Massachusetts and Princeton, New Jersey. For additional information, please visit GPC Biotech's Web site at http://www.gpc-biotech.com.

     For further information, please contact:
     
     
     

     Martin Braendle
     Director, Investor Relations & Corporate Communications
     Phone:  
     

     In the U.S.:  Laurie Doyle
     Director, Investor Relations & Corporate Communications
     Phone:   or  
     

     Additional Media Contacts:

     In Europe:
     Maitland Noonan Russo
     Brian HudspithPhone:  
     

     In the U.S.:
     Noonan Russo
     David Schull
     Phone:  
     

SOURCE